Grade 3–4 adverse events included neutropenia (4/17, 23.5%); proteinuria (1/17, 5.9%) and anemia (1/17, 5.9%) in first-line Bev + CP treatment; leukopenia (1/10, 10.0%); neutropenia (1/10, 10.0%); anemia (1/10, 10.0%) and thrombocytopenia (1/10, 10.0%) in first-line GP treatment, neutropenia (3/13, 23.1%) and anemia (1/13, 7.7%) in further-line Bev + CP treatment. This evidence concerns the gene CP and neutropenia.